Nanoform Finland (OSTO:NANOFS) Inventory-to-Revenue : 0.46 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Nanoform Finland's Average Total Inventories for the quarter that ended in Dec. 2023 was kr2.07 Mil. Nanoform Finland's Revenue for the three months ended in Dec. 2023 was kr4.47 Mil. Nanoform Finland's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.46.

Nanoform Finland's Inventory-to-Revenue for the quarter that ended in Dec. 2023 increased from Sep. 2023 (0.18) to Sep. 2023 (0.46)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Nanoform Finland's Days Inventory for the three months ended in Dec. 2023 was 160.54.

Inventory Turnover measures how fast the company turns over its inventory within a year. Nanoform Finland's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.57.

Nanoform Finland Inventory-to-Revenue Historical Data

The historical data trend for Nanoform Finland's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland Inventory-to-Revenue Chart

Nanoform Finland Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

Get a 7-Day Free Trial

0.04

Nanoform Finland Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventory-to-Revenue	Get a 7-Day Free Trial															0.01	0.05	0.10	0.18	0.46

Competitive Comparison of Nanoform Finland's Inventory-to-Revenue

For the Biotechnology subindustry, Nanoform Finland's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanoform Finland's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoform Finland's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nanoform Finland's Inventory-to-Revenue falls into.

Nanoform Finland Inventory-to-Revenue Calculation

Nanoform Finland's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (0.066	+	2.439)	/	2 )	/	28.703
=	1.2525					/	28.703
=	0.04

Nanoform Finland's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (Q: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Revenue (Q: Dec. 2023 )
=	( (1.692	+	2.439)	/	2 )	/	4.474
=	2.0655					/	4.474
=	0.46

Nanoform Finland (OSTO:NANOFS) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Nanoform Finland's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	2.0655	/	1.174	*	365 / 4
	=	160.54

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Nanoform Finland's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	1.174	/	2.0655
	=	0.57

Nanoform Finland Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanoform Finland (OSTO:NANOFS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OSTO:NANOFS) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

NANOFH:Finland 4YL:Germany

Address

Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790

Website

https://www.nanoform.com

Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland (OSTO:NANOFS) Headlines

No Headlines